Literature DB >> 18330912

PINK1 heterozygous rare variants: prevalence, significance and phenotypic spectrum.

Roberta Marongiu1, Alessandro Ferraris, Tàmara Ialongo, Silvia Michiorri, Francesco Soleti, Francesca Ferrari, Antonio E Elia, Daniele Ghezzi, Alberto Albanese, Maria Concetta Altavista, Angelo Antonini, Paolo Barone, Livia Brusa, Pietro Cortelli, Paolo Martinelli, Maria Teresa Pellecchia, Gianni Pezzoli, Cesa Scaglione, Paolo Stanzione, Michele Tinazzi, Anna Zecchinelli, Massimo Zeviani, Emanuele Cassetta, Barbara Garavaglia, Bruno Dallapiccola, Anna Rita Bentivoglio, Enza Maria Valente.   

Abstract

Heterozygous rare variants in the PINK1 gene, as well as in other genes causing autosomal recessive parkinsonism, have been reported both in patients and healthy controls. Their pathogenic significance is uncertain, but they have been suggested to represent risk factors to develop Parkinson disease (PD). The few large studies that assessed the frequency of PINK1 heterozygotes in cases and controls yielded controversial results, and the phenotypic spectrum is largely unknown. We retrospectively analyzed the occurrence of PINK1 heterozygous rare variants in over 1100 sporadic and familial patients of all onset ages and in 400 controls. Twenty patients and 6 controls were heterozygous, with frequencies (1.8% vs. 1.5%) not significantly different in the two groups. Clinical features of heterozygotes were indistinguishable to those of wild-type patients, with mean disease onset 10 years later than in carriers of two mutations but worse disease progression. A meta-analysis indicated that, in PINK1 heterozygotes, the PD risk is only slightly increased with a non significant odds ratio of 1.62. These findings suggest that PINK1 heterozygous rare variants play only a minor susceptibility role in the context of a multifactorial model of PD. Hence, their significance should be kept distinct from that of homozygous/compound heterozygous mutations, that cause parkinsonism inherited in a mendelian fashion. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18330912     DOI: 10.1002/humu.20719

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  22 in total

Review 1.  Mitochondrial kinases in Parkinson's disease: converging insights from neurotoxin and genetic models.

Authors:  Ruben K Dagda; Jianhui Zhu; Charleen T Chu
Journal:  Mitochondrion       Date:  2009-06-27       Impact factor: 4.160

Review 2.  The role of monogenic genes in idiopathic Parkinson's disease.

Authors:  Xylena Reed; Sara Bandrés-Ciga; Cornelis Blauwendraat; Mark R Cookson
Journal:  Neurobiol Dis       Date:  2018-11-15       Impact factor: 5.996

Review 3.  The Effects of Variants in the Parkin, PINK1, and DJ-1 Genes along with Evidence for their Pathogenicity.

Authors:  David N Hauser; Christopher T Primiani; Mark R Cookson
Journal:  Curr Protein Pept Sci       Date:  2017       Impact factor: 3.272

Review 4.  Gene-environment interactions: key to unraveling the mystery of Parkinson's disease.

Authors:  Hui-Ming Gao; Jau-Shyong Hong
Journal:  Prog Neurobiol       Date:  2011-03-23       Impact factor: 11.685

Review 5.  Tickled PINK1: mitochondrial homeostasis and autophagy in recessive Parkinsonism.

Authors:  Charleen T Chu
Journal:  Biochim Biophys Acta       Date:  2009-07-09

Review 6.  Levodopa-induced dyskinesias and their management.

Authors:  Francesca Del Sorbo; Alberto Albanese
Journal:  J Neurol       Date:  2008-08       Impact factor: 4.849

7.  Parkin and PINK1 mutations in early-onset Parkinson's disease: comprehensive screening in publicly available cases and control.

Authors:  J Brooks; J Ding; J Simon-Sanchez; C Paisan-Ruiz; A B Singleton; S W Scholz
Journal:  J Med Genet       Date:  2009-04-06       Impact factor: 6.318

8.  PINK1 heterozygous mutations induce subtle alterations in dopamine-dependent synaptic plasticity.

Authors:  Graziella Madeo; Tommaso Schirinzi; Giuseppina Martella; E Claudio Latagliata; Francesca Puglisi; Jie Shen; Enza Maria Valente; Mauro Federici; Nicola B Mercuri; Stefano Puglisi-Allegra; Paola Bonsi; Antonio Pisani
Journal:  Mov Disord       Date:  2013-10-25       Impact factor: 10.338

9.  The genetic landscape of high-risk neuroblastoma.

Authors:  Trevor J Pugh; Olena Morozova; Edward F Attiyeh; Shahab Asgharzadeh; Jun S Wei; Daniel Auclair; Scott L Carter; Kristian Cibulskis; Megan Hanna; Adam Kiezun; Jaegil Kim; Michael S Lawrence; Lee Lichenstein; Aaron McKenna; Chandra Sekhar Pedamallu; Alex H Ramos; Erica Shefler; Andrey Sivachenko; Carrie Sougnez; Chip Stewart; Adrian Ally; Inanc Birol; Readman Chiu; Richard D Corbett; Martin Hirst; Shaun D Jackman; Baljit Kamoh; Alireza Hadj Khodabakshi; Martin Krzywinski; Allan Lo; Richard A Moore; Karen L Mungall; Jenny Qian; Angela Tam; Nina Thiessen; Yongjun Zhao; Kristina A Cole; Maura Diamond; Sharon J Diskin; Yael P Mosse; Andrew C Wood; Lingyun Ji; Richard Sposto; Thomas Badgett; Wendy B London; Yvonne Moyer; Julie M Gastier-Foster; Malcolm A Smith; Jaime M Guidry Auvil; Daniela S Gerhard; Michael D Hogarty; Steven J M Jones; Eric S Lander; Stacey B Gabriel; Gad Getz; Robert C Seeger; Javed Khan; Marco A Marra; Matthew Meyerson; John M Maris
Journal:  Nat Genet       Date:  2013-01-20       Impact factor: 38.330

10.  Genetic analysis of PARK2 and PINK1 genes in Brazilian patients with early-onset Parkinson's disease.

Authors:  Karla Cristina Vasconcelos Moura; Mário Campos Junior; Ana Lúcia Zuma de Rosso; Denise Hack Nicaretta; João Santos Pereira; Delson José Silva; Flávia Lima dos Santos; Fabíola da Costa Rodrigues; Cíntia Barros Santos-Rebouças; Márcia Mattos Gonçalves Pimentel
Journal:  Dis Markers       Date:  2013-08-14       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.